In partnership with
Replace 16 supplements in one daily drink.
David Beckham. Giannis Antetokounmpo. Aryna Sabalenka. Inter Miami CF. The world's best choose IM8 because performance starts with what you do every day.
Daily Ultimate Essentials and Longevity deliver a complete, clinically formulated system for energy, digestion, sleep, focus and healthy aging. In a 12-week randomized controlled trial, 95% felt a boost in daily energy, 85% felt less bloated with better digestion, 80% reported better sleep and 75% reported sharper focus and mental clarity.
IM8 is NSF Certified for Sport, tested against 280+ banned substances and recommended by 300+ clinicians. With 50 million servings sold across 46 countries, discover the IM8 routine trusted at the highest levels of sport—and built for everyday life. See the clinical results.
LONGEVITY LATEST ISSUE 28 · 16 SEPTEMBER 2026
LONGEVITY LATEST
The Evidence-Based Edge on Living Longer and Better
Issue 28 · The AI Peptide Pipeline · 16 September 2026
WELCOME
Welcome
Imagine an AI system that designs a peptide for a biological target, estimates stability and toxicity, tests thousands of virtual variants and sends only a handful into the lab. Pieces of that pipeline now exist.
The exciting part is not that AI has replaced clinical trials. It hasn't. The acceleration comes earlier: choosing better targets, generating candidates, rejecting weak ideas faster and designing smarter trials.
This week, we look at generative peptide design, digital twins and a mitochondrial-derived peptide now in Phase 2. The question is not whether AI changes longevity research. It already does. The question is what still has to be proved in people.
SPOTLIGHT
What AI can compress, and what it cannot
Stage | AI can help with | It still cannot prove |
Candidate design | Generate and optimise sequences against defined constraints. | Safety or efficacy in humans. |
Virtual patient models | Simulate selected trajectories, doses and outcomes. | A complete whole-body response over decades. |
Clinical trials | Improve matching, design, monitoring and go/no-go decisions. | Replace human evidence where safety and benefit matter. |
The common error is to treat a simulation as a synthetic person. A digital twin is a model built for a defined context. Its value depends on the data, assumptions and validation behind that use.
Nature Medicine: digital twins and in silico trials (2026) · FDA: ISTAND in silico drug-development tools (2026) · Nature Reviews Drug Discovery: AI in drug discovery (2026)
The acceleration is real. The shortcut to human evidence is not.
THIS WEEK'S ANALYSIS
Top 3 Developments Under the Microscope
These grades describe how far each development has travelled from computation towards clinical use. They do not grade anti-ageing efficacy.
Readiness grades: A = established clinical use; B = human or regulatory development; C = preclinical or early clinical; D = concept only.
1. Generative peptide optimisation | Grade C
AI changed the sequence. The laboratory still had to test it.
The study. In May, researchers reported ApexGO, a generative system that optimised ten peptide templates. They synthesized 100 proposed derivatives and tested them experimentally rather than stopping at computer scores.
The result. The paper reports an 85% experimental hit rate and a 72% success rate for improving activity against Gram-negative pathogens. Selected molecules also worked in two mouse infection models. There were no human trials.
The decision. This is strong evidence that AI can improve peptide candidates under real design constraints. It is not evidence that an AI-designed peptide slows human ageing. The target, biology and clinical endpoint still have to be right.
2. Digital twins and in silico trials | Grade B
The development. Digital twins can model patient trajectories under alternative treatments, while simulation can test trial designs before participants are enrolled. Nature Medicine described these tools as arriving in drug development, with validation and regulatory oversight still central.
The milestone. In June 2026, FDA accepted the first Letter of Intent for an in silico drug-development tool into its ISTAND qualification program. The AI-driven digital liver model is intended to help predict drug-induced liver injury. It has entered the regulatory qualification process, not received blanket approval to replace human testing.
The decision. Expect better candidate selection, dose planning and trial design. Do not translate "in silico" into "human trials are obsolete." A model earns trust one context of use at a time.
3. MOTS-c reaches Phase 2 | Grade C
The trial. A randomized, double-blind Phase 2a study began in February 2026 to test the mitochondrial-derived peptide MOTS-c in 120 adults with prediabetes and overweight or obesity. The 12-week study is measuring insulin sensitivity and standard metabolic outcomes. No efficacy result has been reported yet. The study is not a longevity trial.
HYPE CHECK
“AI can simulate humans, so trials are obsolete”
The claim. Once AI can create virtual patients, drugs and peptides can be validated without exposing real people.
The missing step. Digital twins simulate specified outcomes from available data and assumptions. They do not reproduce every organ, immune interaction, rare adverse event or decades of ageing biology. Their accuracy has to be demonstrated for the decision being made.
FDA's 2026 in silico milestone was acceptance of a Letter of Intent for a tool intended to predict drug-induced liver injury, not permission to replace human participants.
That distinction matters even more in longevity, where the desired outcome is long-term, multi-system health. AI can compress the search. Biology still has the final vote.
Our verdict. Use AI to reject weak candidates earlier and design better experiments. Demand human evidence before calling an intervention a human longevity therapy.
IN BRIEF · NEW RESEARCH
Proteomic clocks move into a drug trial. A Nature Biotechnology paper published 7 September applied six protein-based ageing clocks to samples from a 12-week Phase 2a trial of rentosertib in idiopathic pulmonary fibrosis. All six predicted lower biological age in treated arms, but the authors caution that the clocks cannot cleanly separate ageing effects from disease-specific effects. A useful bridge from last week: more consistent clocks still do not equal proof of longer life.
THIS WEEK'S DEEP DIVE
The AI Peptide Pipeline
Generative models can now propose and optimise peptide sequences, digital twins can simulate selected patient trajectories, and regulators are beginning to evaluate in silico tools. The temptation is to join those facts into one giant shortcut.
The companion article follows the evidence ladder from sequence design to laboratory validation, virtual trials and real humans. It also gives five questions for testing any headline that claims AI has made clinical proof optional.
Read the companion: The AI Peptide Pipeline →
The practical takeaway: ask exactly which stage AI accelerated. A better-designed candidate is not yet a better human outcome.
BIOHACKING CORNER · THE SHORT VERSION
Pick one peptide or 'AI-designed' product you have seen promoted. Trace it backwards: Was the molecule physically tested? Is there randomized human evidence? Was the endpoint a symptom, disease outcome or only a biomarker? Is the product being sold the same formulation that was studied? If one link is missing, lower your certainty rather than raising the dose.
READER PULSE
Which technology should Longevity Latest track most closely through 2030: AI-designed peptides, partial cellular reprogramming, senolytics or digital twins? Reply with one choice and why.
CLOSING
Faster discovery is not the same as faster proof
AI can search spaces that humans cannot, propose molecules nobody has synthesized and make trials more informative. That can remove years of wasted work.
But ageing is not one receptor or one biomarker. It is a long, interacting biological process. The winning future is likely to combine faster machine-designed discovery with stricter experimental validation, not choose one over the other.
Next week: muscle as a longevity asset. How to judge strength, preserve it during weight loss and avoid confusing muscle size with functional reserve.
Stay curious and stay healthy!
Christian Thomsen, Editor
Longevity Latest is published weekly by FrontWave Media Ltd. Educational content, not personal medical advice. Investigational peptides and AI-designed compounds can have unknown risks. Do not start or change treatment on the basis of computational, animal or early-stage evidence; discuss treatment decisions with a qualified clinician who knows your history.
Sources and reading notes
Evidence checked through 13 September 2026 for the 16 September issue. AI and peptide examples are used to explain the drug-development pipeline, not to imply proven anti-ageing benefit.
© 2026 FrontWave Media Ltd · Longevity Latest
Unify Your Teams and Tech Stack With HubSpot
Connect your customer data, teams, and tools without the hassle of complex integrations or lengthy setups. One easy platform gives marketing, sales, and service teams a unified customer view and the tools to turn it into growth.
Why HubSpot and what's new
Generate leads and automate marketing with Marketing Hub
Build your pipeline and close more deals with Sales Hub
Scale customer support and drive retention with Service Hub
Keep customer data clean, connected, and actionable with one, unified platform
Join 306,000+ in over 135 countries using HubSpot to grow their businesses.
See what a more connected approach to growth can do for you and your team. Get setup quickly and start checking off your hardest tasks.